99mTc-Oncardia is the first functional imaging agent for cardiovascular disease. Unlike current nuclear cardiology imaging, referred to as MPI imaging, which images blood flow and requires a rest and stress imaging study, Oncardia uptakes in ischemia as soon as 8 minutes post injection eliminating the stress test for the majority of patients. Cell>Point is completing a Phase 2b/3 trial for cardiac ischemia imaging.
Past, Current and Future Clinical Trial Sites:
Oklahoma Heart Hospital Saint Luke’s Hospital – KC
University of British Columbia Cardiology Consultants of Philadelphia
Great Lakes Medical Research Einstein Clinical Research
Oregon Health and Science Einstein Medical Center
